Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium chloride is the principal extracellular cation and anion, respectively, in the body. It maintains osmotic pressure, fluid balance, and acid-base balance. It is essential for nerve conduction and muscle contraction.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion; dose and rate depend on patient's fluid and electrolyte status; typical maintenance: 0.9% NaCl at 1-2 mL/kg/h.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal half-life is approximately 24-48 hours in healthy individuals, primarily reflecting renal sodium handling and total body sodium pool; significantly prolonged in renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >95% unchanged via glomerular filtration and tubular reabsorption. Fecal/biliary: negligible.
Category C
Category A/B
Electrolyte
Electrolyte